What is it about?
The genomic analysis is essential and more than one site sampling is needed to treat patients with triple negative breast cancer. CNS predilection is a feature of Her2 positive cancer. Our patients original tumor was Her2 negative but the singular CNS metastasis was was Her2 positive. Hence if the sampling is done from the multiple sits one can identify the Her2 positive cancer cells and decide ahead of time how to prevent the CNS metastasis
Featured Image
Why is it important?
Is there the role of Prophylactic CNS treatment in patients with the discordance of Her2 status when the sampling is done from more than one site? Were we able to prevent CNS metastasis by identifying the discordance? These are the thought provoking questions.
Perspectives
I do believe one can select the discordance in the tumor and consider appropriate treatment ahead of time or one can do a randomized study to treat patients with discordance with CNS prophylaxis versus no prophylaxis
Dr suresh b katakkar
Read the Original
This page is a summary of: A triple negative breast cancer: what it is not!, Breast Cancer Targets and Therapy, February 2012, Taylor & Francis,
DOI: 10.2147/bctt.s28449.
You can read the full text:
Contributors
The following have contributed to this page
